MLICM
JBIO

Metropolitan Life Insurance Company (MetLife)’s Jade Biosciences JBIO Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio JBIO Stock Details JBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-20
Closed -$20.7K – 223
2024
Q1 		$20.7K Hold
20
– – ﹤0.01% 1846
2023
Q4 		$15.9K Hold
20
– – ﹤0.01% 2015
2023
Q3 		$9.51K Hold
20
– – ﹤0.01% 2233
2023
Q2 		$12K Hold
20
– – ﹤0.01% 2204
2023
Q1 		$14.1K Hold
20
– – ﹤0.01% 2034
2022
Q4 		$20.5K Buy
+20
New +$14.5K ﹤0.01% 1996

Other funds holding JBIO

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s JBIO Position: Q2 2024 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Jade Biosciences (JBIO) in Q2 2024, closing a stake of 20 shares — an estimated $20.7K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in JBIO in Q4 2022 and held it in 6 quarters. The position peaked at $20.7K in Q1 2024. 80 funds tracked by Wall St. Rank hold JBIO as of Q2 2024.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Jade Biosciences position as of Q2 2024 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 20 Jade Biosciences shares in Q2 2024, an estimated $20.7K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Jade Biosciences in Q4 2022 and held it in 6 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s Jade Biosciences position peaked at $20.7K in Q1 2024.
  • 80 funds tracked by Wall St. Rank held Jade Biosciences as of Q2 2024.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.